Key takeaway
Among 4395 adults aged 60 and older in China, 24.5% of those with possible sarcopenia returned to non-sarcopenia by the next follow-up, while 6.7% progressed to sarcopenia. Follow-up averaged only 3.29 years across three survey waves, so these are short-term transition rates in one country's survey.
Study design
Cohort study
Reading basis
Published abstract
Reading focus
Association & confounding
The research question
Sarcopenia is the age-related loss of muscle mass and function and leads to disability and death. Newer guidelines define a premorbid stage, possible sarcopenia, and recommend early lifestyle intervention, but it was unclear whether people can move back out of that state. The authors studied how people move between non-sarcopenia, possible sarcopenia, sarcopenia and death.
Who and how
Cohort analysis of three waves of the China Health and Retirement Longitudinal Study (CHARLS), a nationally representative survey, between 2011 and 2015. It included community-dwelling people aged 60 and older with at least two sarcopenia assessments based on the Asian Working Group for Sarcopenia 2019 (AWGS2019) criteria. Multi-stage Markov models estimated transition intensities and probabilities between the states, and covariables were examined.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1The study included 4395 people (49.2% female, median age 67 years) with 10 778 assessments and a mean follow-up of 3.29 years.
- 2Of those with possible sarcopenia, by the next follow-up 24.5% returned to non-sarcopenia, 60.3% stayed the same, 6.7% progressed to sarcopenia and 8.5% died.
- 3For possible sarcopenia, the intensity of recovery (0.252, 95% CI 0.231-0.275) was 2.8 times the intensity of deterioration (0.090, 95% CI 0.080-0.100). One-year probabilities were 0.181 for recovery, 0.066 for progression and 0.035 for death.
- 4For people with sarcopenia, one-year probabilities were 0.016 for recovery to non-sarcopenia, 0.125 for recovery to possible sarcopenia and 0.075 for death. Age, sex, body mass index, physical function impairment, smoking, hypertension and diabetes influenced the transitions.
Limits & uncertainty
- 1Mean follow-up was 3.29 years, so the model says little about longer-term trajectories.
- 2Some recovery between assessments may reflect measurement variability around diagnostic cutoffs rather than true muscle change.
- 3The covariable analysis shows what is associated with transitions, not what causes recovery, and the study did not test any intervention.
- 4This reading is based on the abstract only.
What to take from it
Possible sarcopenia is not a one-way street: in this group, recovery was more common than progression. That fits the case for early attention to physical function, but the study does not show which actions drive recovery. Concerns about muscle loss are worth raising with your clinician.
Reading your own data
Sarcopenia is assessed with muscle mass and function tests such as grip strength and walking speed, which a wearable does not provide. You can follow related signs with a body-composition scale, home strength tests done the same way each time, and daily steps. Compare trends over months on the same device and conditions.
How to read this evidence
Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Sarcopenia, the age-related loss of muscle mass and function, brings multiple adverse outcomes including disability and death. Several sarcopenia consensuses have newly introduced the premorbid concept of possible sarcopenia and recommended early lifestyle interventions. Bidirectional transitions of premorbid states have been revealed in several chronic diseases yet not clarified in sarcopenia. This study aims to investigate the underlying transition patterns of sarcopenia states.
Methods
The study utilized three waves of data from a nationally representative survey, the China Health and Retirement Longitudinal Study (CHARLS), and included community-dwelling individuals aged 60 years and older with at least two sarcopenia states assessments based on the Asian Working Group for Sarcopenia criteria 2019 (AWGS2019) between 2011 and 2015. The estimated transition intensity and probability between non-sarcopenia, possible sarcopenia, sarcopenia, and death were investigated using multi-stage Markov (MSM) models.
Results
The study comprised 4395 individuals (49.2% female, median age 67 years) with a total of 10 778 records of sarcopenia state assessment, and the mean follow-up period was 3.29 years. A total of 24.5% of individuals with a current state of possible sarcopenia returned to non-sarcopenia, 60.3% remained possible sarcopenia, 6.7% progressed to sarcopenia, and 8.5% died by the next follow-up. The transition intensity of recovery to non-sarcopenia (0.252, 95% CI 0.231-0.275) was 2.8 times greater than the deterioration to sarcopenia (0.090, 95% CI 0.080-0.100) for individuals with possible sarcopenia. For individuals with possible sarcopenia, the estimated probabilities of recovering to non-sarcopenia, progressing to sarcopenia, and transitioning to death within a 1-year observation were 0.181, 0.066, and 0.035, respectively. For individuals with sarcopenia, the estimated probabilities of recovering to non-sarcopenia, recovering to possible sarcopenia, and transitioning to death within 1-year observation were 0.016, 0.125, and 0.075, respectively. In covariables analysis, age, sex, body mass index, physical function impairment, smoking, hypertension, and diabetes are important factors influencing bidirectional transitions.
Conclusions
The findings highlight the bidirectional transitions of sarcopenia states among older adults and reveal a notable proportion of possible sarcopenia show potential for recovery in the natural course. Screening and intensifying interventions based on risk factors may facilitate a recovery transition.
Sources & attribution
Bidirectional transitions of sarcopenia states in older adults: The longitudinal evidence from CHARLS.
Luo YX, Zhou XH, Heng T, Yang LL, Zhu YH, Hu P, Yao XQ.
Journal of cachexia, sarcopenia and muscle · 2024-07-12
DOI: 10.1002/jcsm.13541 ↗PubMed · 39001569 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

